Nrc Health
NASDAQ: NRC
$21.04 ▲ +0.21  (+1.01%)
At close: Jul 24, 2026 · 3:59 PM UTC
Financial Ratios
Market Cap454.07 Mn
P/E-51.55
P/S3.28
Div. Yield0.03
Total Debt (Qtr)74.02 Mn
Revenue Growth (1y) (Qtr)3.58
Add ratio to table…

About

National Research Corporation provides experience management solutions for the healthcare industry. The company helps healthcare organizations understand patients consumers clinicians employees and communities through data collection analysis and actionable insights. It operates under the brand NRC Health and focuses on humanizing healthcare interactions. The company generates revenue primarily through subscription based service agreements for its suite of solutions.…

Read more ↓
Sector: Healthcare Industry: Health Information Services CIK: 0000070487

Investment Thesis

▲ Bull case
  • National Research Corporation (NRC) is positioned to benefit from a structural shift in healthcare governance that management is strategically amplifying through its Governance Institute. Recent news highlights the formation of a Blue Ribbon Committee on Health System Governance, which aims to redefine board effectiveness in response to growing enterprise complexity from AI integration, digital transformation, and workforce strain. This initiative builds on the Governance Trilogy™ framework introduced in their April 2026 report, which identifies a critical gap: healthcare operations have outpaced traditional governance models. By positioning itself as the architect of next-generation governance through practical tools and assessments, NRC is tapping into a high-value, underserved market where healthcare systems are actively seeking solutions to improve decision quality and feedback loops across interconnected systems. This is not merely an extension of their existing business but a strategic expansion into a domain where board-level consulting and software-enabled governance could command premium pricing and long-term contracts, leveraging NRC’s 45-year credibility in healthcare operations and its recent KLAS award for experience management.
  • NRC’s financial profile demonstrates resilient and improving fundamentals that the market may be underestimating despite recent headline revenue fluctuations. The company reported record Total Recurring Contract Value (TRCV) in Q1 2026, marking the first year-over-year revenue growth since 2023, alongside multi-year highs in both new sales and customer retention. This momentum is underpinned by a 99% recurring revenue mix, which provides exceptional predictability and insulates the business from short-term volatility. Furthermore, the Q1 2026 results show a significant improvement in free cash flow generation, reaching $5.3 million with a 15.4% margin—up from 10.9% in the prior year—driven by disciplined capital expenditure management and strong operating cash flow conversion. Management’s capital allocation strategy, which balances reinvestment in AI-enabled product innovation (such as the beta AI-powered listening feature in Rounding), opportunistic share repurchases, and flexibility for accretive acquisitions, supports sustainable per-share growth. The recent dividend increase to $0.16 per share signals confidence in future cash flow durability, and the company’s ability to expand margins as revenue recovers—currently near 29% adjusted EBITDA margin with upside cited—suggests operating leverage is poised to activate with top-line growth.
  • The Rounding solution and broader enablement portfolio represent a durable and underappreciated growth engine that is gaining traction beyond initial expectations. TRCV from the Rounding solution nearly doubled in 2025 after full platform integration, and the recent beta launch of AI-powered listening capabilities enhances real-time feedback capture, directly addressing healthcare systems’ need for actionable, timely insights to drive quality, safety, and operational improvements. Management emphasized that enablement solutions are not limited to Rounding but extend to workflow automation across discharge planning, care coordination, and frontline guidance—areas where health systems are actively investing to reduce variability and improve outcomes. With 74% penetration among the top 100 U.S. health systems and a Net Promoter Score of 68 reflecting deep customer trust, NRC has a strong foundation to cross-sell these enablement tools into existing accounts. The restructured go-to-market model, aligned with how healthcare systems make decisions, has already driven an 86% year-over-year increase in full-year new sales, indicating that the sales engine is now firing effectively and is scalable into 2026 and beyond.
▼ Bear case
  • National Research Corporation (NRC) faces significant headwinds from macroeconomic and industry-specific pressures that could undermine its growth trajectory despite recent positive momentum. The healthcare IT sector remains sensitive to budget constraints as health systems grapple with margin pressure from rising labor costs, reimbursement uncertainty, and post-pandemic operational strain. Although NRC reported Q1 2026 revenue growth, the full-year 2025 results showed a 4% revenue decline, and the sequential improvement may be partially attributed to lapping a weak comparable period rather than sustained demand strength. The company’s reliance on large health system contracts—while a strength in retention—creates concentration risk; any delay in capital approvals or budget cycles at major accounts could disproportionately impact new sales and expansion revenue. Furthermore, the sales cycle for enablement and governance solutions tends to be long and complex, often requiring multi-stakeholder alignment across clinical, financial, and executive teams, which could delay revenue recognition even as pipeline activity increases.
  • Competitive pressures in the healthcare experience and enablement markets are intensifying, and NRC may be underestimating the threat from both established players and agile entrants. While NRC highlights its KLAS award and 74% penetration among top 100 health systems, the market for patient experience, workflow automation, and governance solutions is crowded with larger technology firms (such as Epic, Cerner, and Press Ganey) and specialized SaaS providers that are rapidly innovating in AI and real-time analytics. The company’s investment in AI-powered features—like the beta listening tool in Rounding—is necessary to keep pace, but it also signals that differentiation is increasingly dependent on technological advancement, where NRC may lack the R&D scale of larger competitors. Additionally, the Governance Institute’s initiatives, while strategically visionary, operate in a niche advisory space that may not translate into scalable, high-margin software revenue; boards often rely on traditional consulting firms for governance assessments, and converting insights into recurring software contracts remains unproven at scale.
  • Financial risks are emerging that could constrain NRC’s ability to execute its growth strategy, particularly around leverage and capital efficiency. The company’s balance sheet shows approximately $74 million in long-term notes payable, and although operating cash flow remains positive, the Q1 2026 financing activities reveal significant outflows from share repurchases ($1.9 million), dividend payments ($3.6 million), and debt servicing, which together exceeded operating cash inflows before financing. While management frames share repurchases as opportunistic and accretive, sustaining them alongside dividend growth and acquisition flexibility could strain liquidity if operating performance falters. Furthermore, the increase in selling, general, and administrative expenses—up nearly 30% year-over-year in Q1 2026—suggests that investments in sales, leadership (such as the David Burik hire), and product development are beginning to pressure the income statement. If revenue growth does not accelerate sufficiently to absorb these costs, margin expansion may be delayed, and the company’s ability to reinvest in innovation while returning capital could be challenged, forcing difficult trade-offs between growth, profitability, and shareholder returns.

Peer Comparison

Companies in the Health Information Services
S.No. Ticker Company Market CapP/EP/STotal Debt (Qtr)
1 VEEV Veeva Systems Inc 29.34 Bn31.168.84-
2 BTSG BrightSpring Health Services, Inc. 13.49 Bn46.180.992.50 Bn
3 HQY Healthequity, Inc. 7.96 Bn34.515.950.94 Bn
4 TXG 10x Genomics, Inc. 6.17 Bn-272.149.65-
5 HNGE Hinge Health, Inc. 6.02 Bn-11.779.31-
6 MMED MiniMed Group, Inc. 4.19 Bn-8.881.38-
7 WAY Waystar Holding Corp. 4.14 Bn32.803.581.47 Bn
8 DOCS Doximity, Inc. 3.82 Bn19.515.93-